InvestorsObserver gives Vertex Pharmaceuticals Incorporated (VRTX) a weak valuation score of 34 from its analysis. The proprietary scoring system considers the underlying health of a company by analyzing its stock price, earnings, and growth rate. VRTX currently holds a better value than 34% of stocks based on these metrics. Long term investors focused on buying-and-holding should find the valuation ranking system most relevant when making investment decisions.
VRTX has a 12 month forward PE to Growth (PEG) ratio of 2.64. Markets are overvaluing VRTX in relation to its projected growth as its PEG ratio is currently above the fair market value of 1. 12.94's PEG comes from its forward price to earnings ratio being divided by its growth rate. PEG ratios are one of the most used valuation metrics due to its incorporation of more company fundamentals metrics and a focus on the firm's future rather than its past.
Is Vertex Pharmaceuticals Incorporated (VRTX) Stock Over or Undervalued?
Mentioned in this article
VRTX gets a 34 Valuation Rank today. Find out what this means to you and get the rest of the rankings on VRTX!